Table 3. . 24-month costs for the percutaneous transluminal angioplasty ‘status quo’ and Tack-supported strategies – non-severe dissection cohort, severe dissection cohort and entire dissection cohort.
| Non-severe dissection cohort (A, B) | Status quo strategy | Tack-supported strategy | Difference | |
|---|---|---|---|---|
| Reimbursement/cost to payers | Index | $11,502 | $14,398 | $2896 |
| Reintervention | $3582 | $984 | -$2598 | |
| Total | $15,084 | $15,381 | $297 | |
| Device costs | Index | $842 | $2787 | $1945 |
| Reintervention | $556 | $198 | -$358 | |
| Total | $1398 | $2984 | $1587 | |
| Margin | Index | $10,660 | $11,611 | $951 |
| Severe dissection cohort (C, D, E, F) | Status quo strategy | Tack-supported strategy | Difference | |
| Reimbursement/cost to payers | Index | $14,398 | $14,398 | $0 |
| Reintervention | $3369 | $1767 | -$1602 | |
| Total | $17,766 | $16,164 | -$1602 | |
| Device costs | Index | $2350 | $2787 | $436 |
| Reintervention | $807 | $364 | -$443 | |
| Total | $3157 | $3150 | -$7 | |
| Margin | Index | $12,047 | $11,611 | -$436 |
| Entire dissection cohort (A, B, C, D, E, F) | Status quo strategy | Tack-supported strategy | Difference | |
| Reimbursement/cost to payers | Index | $13,520 | $14,398 | $877 |
| Reintervention | $3433 | $1529 | -$1904 | |
| Total | $16,953 | $15,927 | -$1026 | |
| Device costs | Index | $1893 | $2787 | $893 |
| Reintervention | $731 | $313 | -$417 | |
| Total | $2624 | $3100 | $476 | |
| Margin | Index | $11,627 | $11,611 | -$16 |
Results stratified into reimbursement/costs to payer, device costs, index procedure provider margins (defined as reimbursement minus device costs). Discounting and general population mortality applied.